Last reviewed · How we verify
Sodium Enoxaparine
Sodium enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Sodium enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | Sodium Enoxaparine |
|---|---|
| Also known as | Clexane (Sodium Enoxaparine), BCD-080 (Sodium Enoxaparine), Clexane placebo, low molecular weight heparin, clexane |
| Sponsor | Biocad |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is administered subcutaneously and has more predictable pharmacokinetics than unfractionated heparin, making it suitable for both treatment and prophylaxis of thromboembolism.
Approved indications
- Prophylaxis of venous thromboembolism in surgical patients
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Prophylaxis in medically immobilized patients
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty (PHASE3)
- Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin (PHASE3)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome (NA)
- A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery (PHASE2)
- Effectiveness & Safety of Ovine Enoxaparin Sodium to Originator Enoxaparin in Non-ST-Segment Elevation ACS Patients (PHASE4)
- Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Enoxaparine CI brief — competitive landscape report
- Sodium Enoxaparine updates RSS · CI watch RSS
- Biocad portfolio CI